Home » USA Broker Ratings » Vertex Pharmaceuticals Incorpor – Consenus Indicates Potential 16.6% Upside

Vertex Pharmaceuticals Incorpor – Consenus Indicates Potential 16.6% Upside

Vertex Pharmaceuticals Incorpor found using ticker (VRTX) now have 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 285 and 200 with the average target price sitting at 228. Now with the previous closing price of 195.48 this indicates there is a potential upside of 16.6%. The 50 day moving average now sits at 178.84 while the 200 day moving average is 175.94. The company has a market capitalisation of $51,649m. Find out more information at: http://www.vrtx.com

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics, as well as a strategic collaboration with Ribometrix, Inc. to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.